SCHEMBL6004294

SCHEMBL6004294

CCCC(=O)Nc1ccc(C=O)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52
LMNA P02545 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 4/20 0.48
ALDH1A1 P00352 3/20 0.48
THRB P10828 2/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004320 0.84 HTT (0.54) POLBGAALMNAMEN1KMT2A
SCHEMBL6004774 0.84 KDM4E (0.46) POLBGAAL3MBTL1MAPTKDM4E
SCHEMBL10029204 0.83 ALDH1A1 (0.67) LMNAL3MBTL1MEN1KMT2AMAPT
SCHEMBL10029201 0.83 MEN1 (0.50) GAALMNAL3MBTL1MEN1KMT2A
SCHEMBL25737020 0.81 MEN1 (0.74) POLBGAALMNAL3MBTL1MEN1
SCHEMBL7013927 0.79 ALDH1A1 (0.52) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL6005086 0.79 SMN1; SMN2 (0.69) GAALMNAL3MBTL1MEN1KMT2A
SCHEMBL11353314 0.78 RAD52 (0.59) POLBGAALMNAL3MBTL1MEN1
SCHEMBL6004315 0.78 MEN1 (0.63) POLBGAALMNAL3MBTL1MEN1
SCHEMBL7069760 0.78 POLB (0.44) POLBMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112441984-B Benzimidazole-substituted phenyl n-butyramide-based compound and preparation method thereof 上海特化医药科技有限公司 2024-04-19 CN claimed
CN-112441984-B Benzimidazole-substituted phenyl n-butyramide-based compound and preparation method thereof 上海特化医药科技有限公司 2024-04-19 CN disclosed
CN-113045501-B Preparation method of telmisartan intermediate 石家庄学院 2022-09-30 CN disclosed
CN-113045501-A Preparation method of telmisartan intermediate 石家庄学院 2021-06-29 CN disclosed
US-20060167087-A1 Substituted aniline derivatives H. LUNDBECK A/S (DK) 2006-07-27 US disclosed
EP-1606247-A1 SUBSTITUTED ANILINE DERIVATIVES H. Lundbeck A/S (DK) 2005-12-21 EP disclosed
WO-2004080950-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167087-A1 Substituted aniline derivatives CYP3A43, UGT2B7, CYP3A7 POLB 2463/4885GAA 200/4885LMNA 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.